- Not Fee assured
- Awaiting verification
Dr Nicholas Van As qualified in medicine in 1995 in South Africa and completed specialist training in clinical oncology at Guy’s and St Thomas’ Hospital, The Royal Marsden and The Institute of Cancer Research.
Dr Van As specialises in urological cancers. He has research interests in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI. He has published numerous papers and delivered presentations at international meetings.
Dr Van As is the clinical lead for CyberKnife and leads the stereotactic radiotherapy MDT at The Royal Marsden. He is the chief investigator on the PACE trial. This is the largest international trial looking at stereotactic radiotherapy for prostate cancer. CyberKnife is an exciting new technology which allows the accurate delivery of high-dose image-guided radiotherapy. It has been operational at The Royal Marsden since summer 2011.
Areas of interest
Urological oncology; Radiotherapy; SBRT; SABR; Cyberknife; Systemic therapy for prostate cacner
Current NHS consultant posts held
Consultant Clinical Oncologist: Royal Marsden Hospital
National Clinical lead for NHS England SABR CtE programme
He has research interests in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI. He is the chief investigator on the PACE trial. This is the largest international trial looking at stereotactic radiotherapy for prostate cancer
(Additional) Languages spoken
Prostate Stereotactic Body Radiotherapy - First UK Experience.
Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, Wells E, Taylor H, Khoo VS, van As NJ.
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):757-61.
Stereotactic body radiotherapy for oligometastases.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA,
Nutting CM, Ostler PJ, van As NJ.
Lancet Oncol. 2013 Jan;14(1):e28-37.
Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?
K Aitken, A Tree, K Thomas, C Nutting, M Hawkins, D Tait, H Mandeville, M Ahmed, S Lalondrelle, A Miah, A Taylor, G Ross, V Khoo, N van As
Clinical Oncology 27(2015) 411-419
A study of diffusion-weighted magnetic resonance imaging in men with
untreated localised prostate cancer on active surveillance.
van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, Parker CC.
Eur Urol. 2009 Dec;56(6):981-7.
Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse.
van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP,
Horwich A, Huddart RA.
Br J Cancer. 2008 Jun17;98(12):1894-902.
Correlation of diffusion-weighted MRI with whole mount radical prostatectomy
Van As N, Charles-Edwards E, Jackson A, Jhavar S, Reinsberg S, Desouza N,
Dearnaley D, Bailey M, Thompson A, Christmas T, Fisher C, Corbishley C, Sohaib S.
Br J Radiol. 2008 Jun;81(966):456-62.
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance.
van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, Horwich A, Dearnaley DP, Parker CC.
Eur Urol. 2008 Dec;54(6):1297-305.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
D Petrylak, N Vogelzang, N Budnik, P Wiechno, C Sternberg, D Kevin, N Van As, N Houede, D Barton ,A Fandi, U Jungnelius U, Li Shaoyi, de Wit Ronald, K Fizazi
Lancet Oncology 16 (April 2015), p417–425
- MBBCh University of Witwatersrand, Johannesburg 1995
- MRCP Royal College Physicians 2000
- FRCR Royal College Radilogists 2004
- MD(res) University of London 2013
Reference number 4295826
Professional bodies (positions held - last 3 yrs)
- Co-Chair UK SABR UK SABR consortium 2015